Back to top
more

Universal Health Services (UHS)

(Delayed Data from NYSE)

$205.26 USD

205.26
632,500

+0.95 (0.46%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $205.49 +0.23 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 11% (28 out of 250)

Industry: Medical - Hospital

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Glaukos (GKOS) Q2 Earnings In Line, Glaucoma Drives Sales

by Zacks Equity Research

Glaukos' (GKOS) second-quarter 2024 results showcase growth in revenues on the back of strong adoption of its glaucoma products like iStent and iDose TR. Loss at the operating level raises concern.

Cencora (COR) Q3 Earnings Beat Estimates, '24 View Raised

by Zacks Equity Research

Cencora's (COR) third-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Humana (HUM) Q2 Earnings Beat on Medicare Advantage Strength

by Zacks Equity Research

Humana's (HUM) second-quarter results reflect overall premium growth and a well-performing CenterWell unit, partly offset by elevated costs. It expects individual MA membership to record growth of 225,000 in 2024.

Inari Medical (NARI) Q2 Earnings Miss, Revenues Increase Y/Y

by Zacks Equity Research

Inari Medical's (NARI) second-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.

GE HealthCare (GEHC) Q2 Earnings Beat Estimates, Net Margin Up

by Zacks Equity Research

GE HealthCare's (GEHC) second-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.

Stryker's (SYK) Q2 Earnings Beat Estimates, Guidance Raised

by Zacks Equity Research

Stryker (SYK) beats second-quarter earnings estimates, driven by robust sales growth and innovative launches like the LIFEPAK 35 and Spine Guidance 5. The company raises 2024 guidance.

DENTSPLY SIRONA (XRAY) Q2 Earnings Miss, Revenues Decline Y/Y

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) second-quarter 2024 results showcase a year-over-year decline in earnings as well as sales.

Zacks.com featured highlights Hilton Grand Vacations, Tenet Healthcare, Universal Health, Popular and B2Gold

by Zacks Equity Research

Hilton Grand Vacations, Tenet Healthcare, Universal Health, Popular and B2Gold have been highlighted in this Screen of The Week article.

Fresenius Medical (FMS) Q2 Earnings In Line, Operating Margin Up

by Zacks Equity Research

Fresenius Medical's (FMS) second-quarter revenues suffer due to divestures. However, the company???s transformational plans continue to benefit its operating income.

Ecolab (ECL) Q2 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Ecolab's (ECL) robust performance across the majority of its segments drives its second-quarter sales amid business challenges.

Baxter's (BAX) Helion Surgical System Debuts in Thailand

by Zacks Equity Research

Baxter (BAX) launches the Helion Integrated Surgical System in Thailand, aiming to streamline operating room efficiency and enhance surgical team connectivity with cutting-edge technology.

Earnings Estimates Moving Higher for Universal Health Services (UHS): Time to Buy?

by Zacks Equity Research

Universal Health Services (UHS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Here's Why Universal Health Services (UHS) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Urmimala Biswas headshot

Bet on These 5 Top-Ranked Value Stocks With Discounted PEG

by Urmimala Biswas

Invest in some top value stocks such as Hilton Grand Vacations (HGV), Tenet Healthcare (THC), Universal Health Services (UHS), Popular, Inc. (BPOP) and B2Gold Corp (BTG) that fit our screening criteria.

Avantor's (AVTR) Q2 Earnings Beat, Operating Margin Declines

by Zacks Equity Research

Avantor's (AVTR) revenues decline in the second quarter with new segmental changes. Bioprocessing orders decline. Operating margin contracts.

Revvity (RVTY) Q2 Earnings Beat Estimates, Guidance Revised

by Zacks Equity Research

Revvity's (RVTY) second-quarter results showcase a decline in life sciences segmental revenues.

Universal Health Services (UHS) Is Up 18.18% in One Week: What You Should Know

by Zacks Equity Research

Does Universal Health Services (UHS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio

by Zacks Equity Research

Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.

DexCom's (DXCM) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

DexCom's (DXCM) second-quarter 2024 earnings surpass expectations while revenues fall short. The Sensor segment and CGM system expansion drive growth. Shares fall.

Hologic (HOLX) Buys Endomag to Boost Breast Cancer Solutions

by Zacks Equity Research

Hologic (HOLX) acquires Endomag for $310M, enhancing its breast cancer surgery portfolio with innovative technologies like Magseed and Magtrace, aiming to improve patient care and outcomes globally.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Universal Health Services, Inc. (UHS) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Why Fast-paced Mover Universal Health Services (UHS) Is a Great Choice for Value Investors

by Zacks Equity Research

Universal Health Services (UHS) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms

by Zacks Equity Research

Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.

Alphatec's (ATEC) New EOS Insight System to Boost Spine Care

by Zacks Equity Research

Alphatec (ATEC) announces the commercial launch of its EOS Insight, an end-to-end spine surgery platform powered by standardized EOSedge scans and artificial intelligence.